GoodRx Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a slight increase in revenue but a notable decline in net income compared to the same period last year. The company generated $196.0 million in revenue for the three months ended September 30, 2025, up from $195.3 million in the prior year. For the nine months ending September 30, 2025, total revenue reached $602.1 million, compared to $593.7 million in the same period of 2024. However, net income fell to $1.1 million, or $0.00 per share, from $4.0 million, or $0.01 per share, in the previous year. The decline in profitability was attributed to increased operating expenses and a higher effective tax rate.
The company experienced a 9% decrease in prescription transactions revenue, which amounted to $127.3 million, primarily due to a reduction in Monthly Active Consumers. This decline was influenced by broader changes in the retail pharmacy landscape, including store closures and a decrease in claims volume from integrated savings programs. Conversely, revenue from pharma manufacturer solutions surged by 54% to $43.4 million, reflecting GoodRx's expanding market penetration in this segment. Subscription revenue also saw a slight decline, dropping 3% to $20.7 million.
GoodRx's operational metrics indicated a decrease in Monthly Active Consumers, which fell to 5.4 million in the third quarter, down from 6.5 million a year earlier. The company reported a total of 671,000 subscription plans as of September 30, 2025, a decrease from 701,000 in the same period of 2024. The company’s total assets decreased to $1.33 billion from $1.39 billion at the end of 2024, while total liabilities increased to $724.8 million, up from $663.4 million.
In terms of strategic developments, GoodRx completed the acquisition of VCRx in January 2025 for $30 million, which is expected to enhance its prescription transactions offering. Additionally, on October 16, 2025, the company acquired ScriptDrop, a prescription delivery technology platform, for $13.5 million, aimed at improving consumer experience in prescription delivery. Looking ahead, GoodRx anticipates continued challenges in the retail pharmacy sector but remains optimistic about long-term growth, particularly in its pharma manufacturer solutions and subscription offerings. The company expects to navigate current market conditions while focusing on expanding its consumer base and enhancing its service offerings.
About GoodRx Holdings, Inc.
GoodRx Holdings, Inc. operates a digital healthcare platform providing price transparency and savings solutions for prescription medications in the U.S. It offers price comparison tools, subscription plans, telehealth services, and pharma manufacturer solutions, serving consumers, healthcare providers, pharmacies, PBMs, and pharma companies. The company's value lies in improving medication affordability, adherence, and access through proprietary technology, industry partnerships, and data-driven insights.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.